30062 Federal Register / Vol. 86, No. 106 / Friday, June 4, 2021 / Notices 

Contact Person: Lystranne Alysia Maynard 

Smith, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Bethesda, MD 20892, (301) 402–4809, 

lystranne.maynard-smith@nih.gov. 

Name of Committee: Genes, Genomes, and 

Genetics Integrated Review Group; 

Therapeutic Approaches to Genetic Diseases 

Study Section. 

Date: June 30–July 1, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Elena Smirnova, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5187, 

MSC 7840, Bethesda, MD 20892, (301) 357– 

9112, smirnove@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Physiology and Pathobiology of 

the Vascular and Hematological Systems. 

Date: June 30, 2021. 

Time: 9:30 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Larry Pinkus, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4132, 

MSC 7802, Bethesda, MD 20892, (301) 435– 

1214, pinkusl@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Cancer Biology. 

Date: June 30, 2021. 

Time: 1:00 p.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Juraj Bies, Ph.D., Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Rm. 4158, MSC 7806, Bethesda, MD 

20892, (301) 435–1256, biesj@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: June 1, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–11782 Filed 6–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice of Diabetes Mellitus Interagency 

Coordinating Committee Meeting 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The Diabetes Mellitus 

Interagency Coordinating Committee 

(DMICC) will hold a joint meeting with 

the National Institutes of Arthritis and 

Musculoskeletal and Skin Diseases on 

June 4, 2021. The topic for this meeting 

will be ‘‘Diabetes and Bone.’’ The 

meeting is open to the public. 

DATES: The meeting will be held on June 

4, 2021 from 11 a.m. to 1:00 p.m. EDT. 

ADDRESSES: The meeting will be held 

via the online video conferencing Zoom. 

For details, and to register, please 

contact dmicc@mail.nih.gov. 

FOR FURTHER INFORMATION CONTACT: For 

further information concerning this 

meeting, including a draft agenda, see 

the DMICC website, 

www.diabetescommittee.gov, or contact 

Dr. B. Tibor Roberts, Executive 

Secretary of the Diabetes Mellitus 

Interagency Coordinating Committee, 

National Institute of Diabetes and 

Digestive and Kidney Diseases, 31 

Center Drive, Building 31A, Room 

9A19, MSC 2560, Bethesda, MD 20892– 

2560, telephone: 301–496–6623; FAX: 

301–480–6741; email: dmicc@

mail.nih.gov. 

SUPPLEMENTARY INFORMATION: In 

accordance with 42 U.S.C.285c–3, the 

DMICC, chaired by the National 

Institute of Diabetes and Digestive and 

Kidney Diseases (NIDDK) comprising 

members of the Department of Health 

and Human Services and other federal 

agencies that support diabetes-related 

activities, facilitates cooperation, 

communication, and collaboration on 

diabetes among government entities. 

DMICC meetings, held several times a 

year, provide an opportunity for 

Committee members to learn about and 

discuss current and future diabetes 

programs in DMICC member 

organizations and to identify 

opportunities for collaboration. The 

June 4, 2021 DMICC meeting will focus 

on ‘‘Diabetes and Bone.’’ 

Any member of the public interested 

in presenting oral comments to the 

Committee should notify the contact 

person listed on this notice at least 5 

days in advance of the meeting. 

Interested individuals and 

representatives or organizations should 

submit a letter of intent, a brief 

description of the organization 

represented, and a written copy of their 

oral presentation in advance of the 

meeting. Only one representative of an 

organization will be allowed to present; 

oral comments and presentations will be 

limited to a maximum of 5 minutes. 

Printed and electronic copies are 

requested for the record. In addition, 

any interested person may file written 

comments with the Committee by 

forwarding their statement to the 

contact person listed on this notice. The 

statement should include the name, 

address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Because of time constraints for the 

meeting, oral comments will be allowed 

on a first-come, first-serve basis. 

Members of the public who would 

like to receive email notification about 

future DMICC meetings should register 

for the listserv available on the DMICC 

website, www.diabetescommittee.gov. 

Dated: May 19, 2021. 

Bruce Tibor Roberts, 

Executive Secretary, DMICC, Office of 

Scientific Program and Policy Analysis, 

National Institute of Diabetes and Digestive 

and Kidney Diseases, National Institutes of 

Health. 

[FR Doc. 2021–11728 Filed 6–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Cancer 

Advisory Board and NCI Board of 

Scientific Advisors. 

The meeting will be held as a virtual 

meeting and is open to the public as 

indicated below. Individuals who plan 

to view the virtual meeting and need 

special assistance or other reasonable 

accommodations to view the meeting 

should notify the Contact Person listed 

below in advance of the meeting. The 

meeting will be videocast and can be 

accessed from the NIH Videocasting and 

Podcasting website (http://

videocast.nih.gov/). 

A portion of the National Cancer 

Advisory Board meeting will be closed 

to the public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

Federal Register / Vol. 86, No. 106 / Friday, June 4, 2021 / Notices 30063 

1 50 U.S.C. 4558(c)(1). 

2 85 FR 18403 (Apr. 1, 2020). 

3 DHS Delegation 09052, Rev. 00.1 (Apr. 1, 2020); 

DHS Delegation Number 09052 Rev. 00 (Jan. 3, 

2017). 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Advisory Board and NCI Board of Scientific 

Advisors. 

Date: June 14, 2021. 

Open: 11:00 a.m. to 12:00 p.m. 

Agenda: NCAB Subcommittee Meetings— 

Subcommittee on Planning and Budget. 

Open: 12:05 p.m. to 4:00 p.m. 

Agenda: Joint meeting of the National 

Cancer Advisory Board and NCI Board of 

Scientific Advisors, NCI Director’s report and 

presentations. 

Closed: 4:00 p.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute—Shady 

Grove, 9609 Medical Center Drive, Rockville, 

MD 20850 (Virtual Meeting). 

Name of Committee: National Cancer 

Advisory Board and NCI Board of Scientific 

Advisors. 

Date: June 15, 2021. 

Open: 1:00 p.m. to 3:00 p.m. 

Agenda: Joint meeting of the National 

Cancer Advisory Board and NCI Board of 

Scientific Advisors, NCI Board of Scientific 

Advisors Concepts Review, Ongoing and 

New Business. 

Place: National Cancer Institute—Shady 

Grove, 9609 Medical Center Drive, Rockville, 

MD 20850 (Virtual Meeting). 

Contact Person: Paulette S. Gray, Ph.D. 

Director, Division of Extramural Activities, 

National Cancer Institute—Shady Grove, 

National Institutes of Health, 9609 Medical 

Center Drive, 7th Floor, Room. 7W444, 

Bethesda, MD 20892, 240–276–6340, grayp@

mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

NCAB: https://deainfo.nci.nih.gov/ 

advisory/ncab/ncabmeetings.htm, 

BSA: https://deainfo.nci.nih.gov/advisory/ 

bsa/bsameetings.htm, where an agenda and 

any additional information for the meeting 

will be posted when available. 

This notice is being published less than 15 

days prior to the meeting due to scheduling 

difficulties. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: June 1, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–11783 Filed 6–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Board of Scientific 

Counselors, National Cancer Institute. 

The meeting will be closed to the public 

as indicated below in accordance with 

the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Cancer Institute, including 

consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, National Cancer Institute. 

Date: July 12–13, 2021. 

Time: 11:00 a.m. to 5:30 p.m. 

Agenda: To review and evaluate personnel 

qualifications and performance, and 

competence of individual investigators. 

Place: National Cancer Institute—Shady 

Grove, 9609 Medical Center Drive, Rockville, 

MD 20850 (Virtual Meeting). 

Contact Person: Brian E. Wojcik, Ph.D., 

Senior Review Administrator, Institute 

Review Office, Office of the Director, 

National Cancer Institute, National Institutes 

of Health, 9609 Medical Center Drive, Room 

3W414, Rockville, MD 20850, 240–276–5660, 

wojcikb@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: June 1, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–11784 Filed 6–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID FEMA–2020–0016] 

Meetings To Implement Pandemic 

Response Voluntary Agreement Under 

Section 708 of the Defense Production 

Act 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: Announcement of meetings. 

SUMMARY: The Federal Emergency 

Management Agency (FEMA) held two 

meetings to implement the Voluntary 

Agreement for the Manufacture and 

Distribution of Critical Healthcare 

Resources Necessary to Respond to a 

Pandemic. 

DATES: The first meeting took place on 

Tuesday, May 25, 2021, from 10:30 a.m. 

to 12 p.m. Eastern Time (ET). The 

second meeting took place on 

Wednesday, May 26, 2021, from 2 to 3 

p.m. ET. 

FOR FURTHER INFORMATION CONTACT: 

Robert Glenn, Office of Business, 

Industry, Infrastructure Integration, via 

email at OB3I@fema.dhs.gov or via 

phone at (202) 212–1666. 

SUPPLEMENTARY INFORMATION: Notice of 

these meetings is provided as required 

by section 708(h)(8) of the Defense 

Production Act (DPA), 50 U.S.C. 

4558(h)(8), and consistent with 44 CFR 

part 332. 

The DPA authorizes the making of 

‘‘voluntary agreements and plans of 

action’’ with representatives of industry, 

business, and other interests to help 

provide for the national defense.1 The 

President’s authority to facilitate 

voluntary agreements with respect to 

responding to the spread of COVID–19 

within the United States was delegated 

to the Secretary of Homeland Security 

in Executive Order 13911.2 The 

Secretary of Homeland Security further 

delegated this authority to the FEMA 

Administrator.3

On August 17, 2020, after the 

appropriate consultations with the 

Attorney General and the Chairman of 

the Federal Trade Commission, FEMA 

completed and published in the Federal 

Register a ‘‘Voluntary Agreement, 

Manufacture and Distribution of Critical 

Healthcare Resources Necessary to